PolyNovo 대차 대조표 상태

재무 상태 기준 확인 5/6

PolyNovo 의 총 주주 지분은 A$72.1M 이고 총 부채는 A$2.6M, 이는 부채 대 자기자본 비율을 3.6% 로 가져옵니다. 총자산과 총부채는 각각 A$108.7M 및 A$36.6M 입니다. PolyNovo 의 EBIT는 A$897.0K 이며 이자보상배율은 -1.1 입니다. A$46.0M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

3.6%

부채 비율

AU$2.63m

부채

이자 보상 비율	-1.1x
현금	AU$45.96m
주식	AU$72.12m
총 부채	AU$36.60m
총 자산	AU$108.72m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: PNV 의 단기 자산 ( A$79.3M )이 단기 부채( A$23.2M ).

장기 부채: PNV 의 단기 자산( A$79.3M )이 장기 부채( A$13.3M ).

부채 대 자본 내역 및 분석

부채 수준: PNV 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: PNV 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 3.6% 로 증가했습니다.

부채 범위: PNV 의 부채는 영업 현금 흐름 ( 140% )에 의해 잘 충당되었습니다.

이자 보장: PNV 지불하는 것보다 더 많은 이자를 벌기 때문에 이자 지불 보장은 문제가 되지 않습니다.

PolyNovo 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 20% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: EPS: AU$0.008 (vs AU$0.007 loss in FY 2023)

Now 23% undervalued

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

Now 21% undervalued

Now 20% undervalued

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Forecast breakeven date pushed back to 2024

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.007 loss in FY 2021)

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

Independent Non-Executive Chairman recently bought AU$434k worth of stock

First half 2022 earnings: EPS in line with expectations, revenues disappoint

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Full year 2021 earnings released

Forecast to breakeven in 2023

PolyNovo Limited Provides an Update on its Hernia Device

Non-Executive Independent Director recently sold AU$571k worth of stock

Independent Non-Executive Chairman recently bought AU$721k worth of stock

PolyNovo Announces It has Received Final Independent Review Board

Revenue beats expectations

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in 1H 2020)

New 90-day low: AU$2.42

New 90-day high: AU$3.55

PolyNovo Limited Announces the Breast Device Development Program with Establishment Labs

Non-Executive Independent Director recently sold AU$1.2m worth of stock

PolyNovo Limited Announces US FDA Approves Pivotal Trial IDE

New 90-day high: AU$3.03

New 90-day high: AU$2.74

New 90-day high: AU$2.38

PolyNovo Appoints Innova Medical Oy to Sell Novosorb® BTM in Finland

Independent Non-Executive Chairman recently bought AU$1.0m worth of stock

New 90-day low - AU$2.02

Full year earnings released - AU$0.0063 loss per share

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기